LEVI & Korsinsky Corrects Class Action Notice Against Savara Inc.

New York – On October 29, 2025, the law firm Levi & Korsinsky, LLP issued a correction regarding a previously announced securities‑fraud class action involving Savara Inc. (NASDAQ: SVRA). The initial release incorrectly stated that Levi & Korsinsky filed the suit; the actual complaint was filed by Pomerantz LLP. There are no other changes to the case announcement. The class action alleges that Savara misled investors between March 4, 2024 and May 23, 2025 by making false or concealed statements about its investigational therapy, MOLBREEVI, including issues with its chemistry, manufacturing, and controls; the likelihood of FDA approval; a missed submission timeline; and a heightened need for additional capital. The complaint asserts these misrepresentations caused shareholder losses. Investors who suffered losses in Savara shares during the period may learn about rights to recovery at no cost or obligation. Contact Levi & Korsinsky’s shareholder advocacy team for details. #Savara #LeviKorsinsky #SecuritiesFraud #ClassAction #SlimScan #GrowthStocks #CANSLIM